Bayer’s Uneven Week: A Farmer-Friendly Retreat, a Weizen Wager, and a Quiet Pharma Push
Published on 07/23/2026 at 07:20 | Redaktion boerse-global.de
Bayer’s share price slipped again on Wednesday, closing at €46.61, a drop of 2.04% from the prior session, as the market digested a flurry of corporate activity that ranged from a strategic climbdown on glyphosate tariffs to a long-range bet on hybrid wheat. The stock remains up roughly 26% year-to-date, though it now sits 13.46% below the 52-week high of €53.86 touched in early July.
The most immediate news came from the trade front. Bayer’s subsidiary Ruveon, the former Monsanto unit, formally withdrew its petition at the U.S. International Trade Commission seeking anti-dumping duties of up to 446% on Chinese glyphosate imports. The reversal followed fierce opposition from the National Corn Growers Association and the American Soybean Association, who warned that such steep tariffs would hammer U.S. farmers already grappling with tight margins. Bayer cited its commitment to agricultural customers as the reason for pulling the application, a move that underscores just how carefully the company must tread to maintain goodwill with its core farming clientele.
On the crop science side, Bayer is thinking further ahead. The company signed a licensing agreement with French plant breeder RAGT to develop hybrid wheat varieties, targeting a commercial launch in Europe and North America by the early 2030s. Hybrid wheat promises a step-change in yield potential over conventional varieties, though neither party disclosed specific revenue or investment figures for the project. It is a reminder that Bayer’s agricultural ambitions extend well beyond glyphosate and into new crop technologies.
In pharmaceuticals, two separate collaborations caught attention. Bayer extended its long-running partnership with the World Health Organization to combat three neglected tropical diseases—Chagas, sleeping sickness, and tapeworm infections—through 2030. The company is donating 18 million tablets and vials valued at $15.5 million, plus $9.45 million in financial support for related programs. The WHO noted that between 2020 and 2025, ten countries eliminated sleeping sickness as a public health problem, with just 546 cases of the gambiense form and 37 of the rhodesiense form reported globally in 2024.
Should investors sell immediately? Or is it worth buying Bayer?
Separately, Bayer announced a clinical collaboration with U.S. biotech Kairos Pharma to test its antibody ENV-105 alongside Bayer’s own Xofigo (radium-223) in patients with metastatic castration-resistant prostate cancer. The aim is to improve outcomes in treatment-resistant cases and expand the drug’s market potential.
On the balance sheet front, Bayer confirmed in July a €3 billion minority investment from Apollo Global Management into a new entity housing its long-acting contraceptive business. Bayer retains majority control and full operational control, with the fresh capital earmarked for debt reduction and managing upcoming bond maturities.
The company also showcased progress on an alternative revenue stream at Canada’s Ag in Motion trade show: Camelina, an oilseed marketed under the newgold brand, which serves as a feedstock for sustainable aviation fuel and biodiesel. A May alliance with BP is driving North American cultivation, leveraging Bayer’s acquisition of Smart Earth Camelina to offer farmers a new cash crop outside traditional rotations.
Bayer at a turning point? This analysis reveals what investors need to know now.
A looming patent cliff remains a concern, with Bayer and Merck & Co. reportedly seeking ways to cushion the revenue impact from expiring patents as smaller competitors eye the resulting market gaps. No specific financial details were provided.
Bayer is scheduled to report second-quarter results on August 4. Analysts will be watching closely for updates on the full-year adjusted profit forecast and any new details on the U.S. litigation landscape.
Ad
Bayer Stock: New Analysis - 23 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
